Truist cuts AxoGen stock price target to $53 on dilution concerns

Barclays initiated coverage on 26 medical device makers, rating Stryker (SYK) and Abbott Laboratories (ABT) as Overweight. Analyst Christopher Pasquale cited compelling valuations and a potential stabilization of revenue as catalysts. Price targets were set for several companies, including SYK at $375 and ABT at $120.

Barclays initiated coverage on Axogen with an Overweight rating and a $55 price target. The rating is based on valuation, EPS revisions, and visibility. Axogen's stock is currently trading at $36.31, down 2.44% over 5 days and 14.44% year-to-date.

Axogen, Inc. (AXGN) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Axogen Completes Acquisition of BioCircuit Technologies, Adding NerveTape™, the First FDA Cleared Device for Sutureless Peripheral Nerve Repair ALACHUA and TAMPA, FL – October 1, 2026 - Axogen, Inc. (“Axogen” or the “Company”) (Nasdaq: AXGN), a global leader in devel

Axogen, Inc. agreed to acquire BioCircuit Technologies, Inc. for $200 million in cash, expected to close in Q4 2026. BioCircuit's NerveTape™ technology, which simplifies nerve repair, complements Axogen's portfolio. The deal is expected to boost revenue growth, adjusted EBITDA margin, and adjusted earnings per share post-closing, while maintaining positive free cash flow, according to Axogen.

Axogen (AXGN) raised $208.7m via a share offering at $42.50 each, alongside an M&A call. The company's stock is up 36% YTD and 157% over 1 year, but down 13% in the past month. Analysts estimate a fair value of $53.22, highlighting potential undervaluation and growth prospects, but also noting valuation risks and dependence on a single product.

Axogen Inc. (AXGN) agreed to acquire BioCircuit Technologies for $200M in cash, funding the deal via a $208.7M stock offering. BioCircuit's NerveTape, an FDA-approved sutureless nerve repair device, will expand Axogen's surgical solutions. AXGN shares fell 10.54% to $45.46 on the news.